{{Drugbox
| verifiedrevid = 447931055
| IUPAC_name = 6,7,8,14-tetrahydro- N-(Cyclopropylmethyl)- 7α-(1-hydroxy-1-methylethyl)- 6,14-endo-ethenonororipavine
| image =Cyprenorphine structure.svg
| width = 220

<!--Clinical data-->
| tradename =  
| legal_US = Schedule I
| legal_status =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4406-22-8
| ATC_prefix = none
| PubChem = 544534
| ChEMBL = 2106063
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16735758
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1P6HEG5ZHS

<!--Chemical data-->
| C=26 | H=33 | N=1 | O=4 
| molecular_weight = 423.545 g/mol
| smiles = CC(C)(O)[C@H]7C[C@]53/C=C/[C@]7(OC)[C@@H]1Oc6c2c(C[C@H]5N(CC[C@@]123)CC4CC4)ccc6O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H33NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-9,15,18-19,22,28-29H,4-5,10-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VSKIOMHXEUHYSI-KNLIIKEYSA-N
}}

'''Cyprenorphine''' ('''M-285''') is an [[opioid]] [[drug]]. It is related to more well-known opioids such as [[buprenorphine]], which is used as an [[analgesic]] and for the treatment of opioid [[Substance dependence|addiction]], and [[diprenorphine]], which is used as an [[antidote]] to reverse the effects of other opioids.

Cyprenorphine has mixed [[agonist–antagonist]] effects at opioid receptors, like those of buprenorphine. However the effects of cyprenorphine are somewhat different, as it produces pronounced [[dysphoric]] and [[hallucinogenic]] effects which limit its potential use as an analgesic.<ref>Bentley KW, Boura ALA, Fitzgerald AE, Hardy DG, McCoubrey A, Aikman ML, Lister RE. Compounds Possessing Morphine-Antagonizing or Powerful Analgesic Effects. ''Nature'', 1965; (206):102-103.</ref><ref>Lowe G, Williams DI. Some Effects of a Hallucinogenic Compound (Cyprenorphine Hydrochloride; M 285) on the Light Reinforced Behaviour of Rats. ''Nature''. 1969; (224):1226.</ref>

Cyprenorphine also has been shown to suppress the intake of sweet solution <ref>{{cite journal|last1=Calcagnetti|first1=Daniel J.|last2=Calcagnetti|first2=Robin Lynn|last3=Fanselow|first3=Michael S.|title=Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine and MR2266, suppress intake of a sweet solution|journal=Pharmacology Biochemistry and Behavior|date=January 1990|volume=35|issue=1|pages=69–73|doi=10.1016/0091-3057(90)90206-W}}</ref> but doesn't suppress the increase in food consumption that's produced by the alpha-2-adrenoceptor antagonist idazoxan. Idazoxan may lead to the release of endogenous opioid peptides and increase food intake, this effect is attenuated by (-)-naloxone but not by the mu/delta-antagonist cyprenorphine. <ref>{{cite journal|last1=Jackson|first1=Helen C.|last2=Griffin|first2=I.J.|last3=Nutt|first3=D.J.|title=Endogenous opioids may be involved in idazoxan-induced food intake|journal=Neuropharmacology|date=August 1992|volume=31|issue=8|pages=771–776|doi=10.1016/0028-3908(92)90040-V}}</ref>

==References==
{{Reflist|2}}


{{Hallucinogens}}
{{Opioidergics}}

[[Category:Alcohols]]
[[Category:Cycloalkenes]]
[[Category:Ethers]]
[[Category:Kappa agonists]]
[[Category:Morphinans]]
[[Category:Phenols]]
[[Category:Semisynthetic opioids]]


{{analgesic-stub}}